Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
89.24
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
Analyst Ratings For Blueprint Medicines
October 24, 2024
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 08, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2024
Via
Benzinga
15 Analysts Have This To Say About Blueprint Medicines
July 29, 2024
Via
Benzinga
Expert Ratings For Blueprint Medicines
June 28, 2024
Via
Benzinga
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
June 07, 2024
Via
Benzinga
Unveiling 18 Analyst Insights On Blueprint Medicines
May 14, 2024
Via
Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
April 26, 2024
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm
May 26, 2024
From
Schall Law
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
May 17, 2024
Via
Benzinga
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
May 02, 2024
Via
Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
April 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 01, 2024
Via
Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
February 20, 2024
Via
Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High
February 16, 2024
Via
Investor Brand Network
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
February 15, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Blueprint Medicines's Earnings Outlook
February 14, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
February 13, 2024
Via
Benzinga
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
February 15, 2024
The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report.
Via
Investor's Business Daily
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
January 09, 2024
Via
Benzinga
Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
December 22, 2023
Via
Benzinga
Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?
December 13, 2023
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
Via
Talk Markets
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
The Latest Analyst Ratings for Blueprint Medicines
December 11, 2023
Via
Benzinga
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
October 27, 2023
Via
Benzinga
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
October 27, 2023
Via
Benzinga
Why Blueprint Medicines Stock Soared Today
October 26, 2023
The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.